Estimating the indirect costs associated with psoriasis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Background. The assessment of indirect economic costs associated with psoriasis is relevant due to the poor knowledge of the impact of the disease on key performance indicators, as well as the question of how the expansion of the pool of patients receiving genetically engineered biological drugs affects the indirect costs associated with the disease.

Aim. Evaluation of the indirect economic burden of psoriasis associated with missed work time and reduced performance in the actual presence at the workplace, as well as an assessment of the impact of changing the structure of therapy on indirect costs.

Material and methods. To calculate the indirect economic burden of psoriasis using the human capital method, two approaches were used: through an assessment of the impact on gross domestic product and through the use of the market value of working hours. A Bayesian network meta-analysis was performed to assess the impact of genetically engineered biologics on the indirect economic costs associated with psoriasis. Systematic search and selection of studies for network meta-analysis was performed using several databases (, Eu Clinical Trials, Pubmed, WHO ICTRP, medRxiv). Studies in patients with moderate to severe psoriasis treated with any genetically engineered biological drug were included.

Results. Indirect economic losses calculated through the assessment of the impact on the gross domestic product amounted to 10.2 billion rubles per year, and through the application of the market value of working time — 17.9 billion rubles per year per 100,000 patients with psoriasis in 2018 in Russian Federation. The genetically engineered biological drugs prescription can lead to a reduction in the annual indirect economic burden by 4.9 billion rubles and 8.6 billion rubles per 100,000 economically active patients with moderate and severe psoriasis, calculated through the assessment of the impact on the gross domestic product and through the application of the market value of working hours, respectively.

Conclusion. A decrease in the work productivity of patients with psoriasis leads to significant indirect costs, while an increase in the proportion of patients receiving genetically engineered biological drugs leads to a decrease in the indirect economic burden on the state and society as a whole.

Full Text

Restricted Access

About the authors

Evgeniya A. Novoderezhkina

Peoples' Friendship University of Russia

Author for correspondence.
ORCID iD: 0000-0002-7657-5973

PhD student

Russian Federation, Moscow, Russia

Sergey K. Zyryanov

Peoples' Friendship University of Russia

ORCID iD: 0000-0002-6348-6867

M.D., D. Sci. (Med.), Prof., Head of Depart., Depart. of General and Clinical Pharmaco­logy chair

Russian Federation, Moscow, Russia


  1. Omelyanovsky VV, Av-xenteva MV, Derkach EV, Sveshnikova ND. Methodological issues of cost of illness analysis. Medical Technologies. Assessment and choice. 2011;(1):42–50. (In Russ.)
  2. Obshcherossiyskaya obshchestvennaya organizatsiya “Rossiyskoe obshchestvo dermatovenerologov i kosmetologov”. Klinicheskie rekomendatsii. Psoriaz. (All-Russian public organization “Russian Society of Dermatovenereologists and Cosmetologists”. Clinical guidelines. Psoriasis. 2020.)!/recomend/866 (access date: 15.08.2021). (In Russ.)
  3. Yagudina RI, Serpik VG. Metodologiya analiza zatrat. Farmakoekonomika: teoriya i praktika. 2016;4(2):3–14. (In Russ.)
  4. Yagudina RI, Kulikov AYu, Serpik VG. Farmakoekonomika. Uchebnoe posobie. (Pharmacoeconomics. Tutorial.) Rostov-na-Donu: Feniks; 2018. 237 p. (In Russ.)
  5. Allen H, Bunn WB, Naim AB. The self-reported health and productivity burden of autoimmune disorders at a major self-insured employer. J Occup Environ Med. 2012;54(9):1049–1063. doi: 10.1097/JOM.0b013e3182602447.
  6. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011. PLoS One. 2012;7(12):e52935. doi: 10.1371/journal.pone.0052935.
  7. Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Ger Soc Dermatology. 2005;3(7):511–518. doi: 10.1111/j.1610-0387.2005.05729.x.
  8. Levy AR, Davie AM, Brazier NC, Jivraj F, Albrecht LE, Gratton D. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012;51(12):1432–1440. doi: 10.1111/j.1365-4632.2011.05359.x.
  9. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213(2):102–110. doi: 10.1159/000093848.
  10. Jacobs P, Bissonnette R, Guenther LC. Socioeconomic burden of immune-mediated inflammatory diseases — Focusing on work productivity and disability. J Rheumatol. 2011;38:55–61. doi: 10.3899/jrheum.110901.
  11. Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics. 2020;31(7):537–549. doi: 10.1007/s40273-013-0056-3.
  12. Schultz AB, Chen CY, Edington DW. The cost and impact of health conditions on presenteeism to employers: a review of the literature. Pharmacoeconomics. 2019;27(5):365–378. doi: 10.2165/00019053-200927050-00002.
  13. Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59(5):772–780. doi: 10.1016/j.jaad.2008.06.043.
  14. Olsen JA, Richardson J. Production gains from health care: What should be included in cost — effectiveness analyses? Soc Sci Med. 1999;49(1):17–26. doi: 10.1016/s0277-9536(99)00116-1.
  15. Ivahnenko OI, Avksenteva MV, Maksimova LV. Methods for estimating indirect costs in health technology assessment. Medical Technologies. Assessment and choice. 2013;(1):29–35. (In Russ.)
  16. Kvamme MK, Lie E, Kvien TK, Kristiansen IS. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. Rheumatology (Oxford). 2020;51(9):1618–1627. doi: 10.1093/rheumatology/kes074.
  17. Pritchard C, Sculpher M. Productivity costs: Principles and practice in economic evaluation. Office of Health Economics; 2000. p. 1–105.
  18. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14(2):171–189. doi: 10.1016/0167-6296(94)00044-5.
  19. Van Den Hout WB. The value of productivity: Human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(1):89–91. doi: 10.1136/ard.2009.117150.
  20. Williams A. Cost-effectiveness analysis: Is it ethical? J Med Ethics. 1992;18(1):7–11. doi: 10.1136/jme.18.1.7.
  21. Central'nyy nauchno-issledovatel'skiy institut organizatsii i informatizatsii zdravookhraneniya. (Central Research Institute of Health Organization and Informatization.) (access date: 02.08.2021). (In Russ.)
  22. Statisticheskiy sbornik, 2017 god. (Statistical compendium, 2017.) Ministerstvo zdravookhraneniya Rossiyskoy Federatsii; 2018. (access date: 08.10.2020). (In Russ.)
  23. Federal'naya sluzhba gosudarstvennoy statistiki. Rynok truda, zanyatost' i zarabotnaya plata. (Federal State Statistics Service. Labor market, employment and wages.) (access date: 16.10.2020). (In Russ.)
  24. Demidenko M, Kuznetsov A. Estimating Equilibrium Real GDP Using a Production Function. Bankaўski vesnik. 2011;(4):42–46. (In Russ.)
  25. Bakulev AL, Fitileva TV, Novoderezhkina EA, Gillotyu I, Tian Kh, Khove T, Pietri G. Psoriasis: clinical and epidemiological features and therapy issues. Vestnik dermatologii i venerologii. 2018;94(3):67–76 (In Russ.) doi: 10.25208/0042-4609-2018-94-3-67-76.
  26. Krichevskaya OI, Vakulenko OYu, Goryachev DV, Erdes ShF. SOME Approaches to quantitative evaluation of reduced productivity in subjects with rheumatic diseases. Rheumatology science and practice. 2012;54(5):90–97. (In Russ.) doi: 10.14412/1995-4484-2012-1188.
  27. Pshenichnikova SN, Romanyuk ID. Analysis of Cobb–Douglas production function for the economies of russia and several countries of the cee-region. Izvestiya Yugo-Zapadnogo gosudarstvennogo universiteta. Seriya: Ekonomika. Sotsiologiya. Menedzhment. 2017;7(3):148–166. (In Russ.)
  28. (access date: 16.10.2020).
  29. EU Clinical Trials Register. (access date: 02.08.2021).
  30. PubMed. (access date: 02.08.2021).
  31. International Clinical Trials Registry Platform (ICTRP). (access date: 02.08.2021).
  32. — the preprint server for Health Sciences. (access date: 02.08.2021).
  33. Omelyanovskiy VV, Khachatryan GR, Nikitina AV, Antonov AA, Vasilyeva YuV. Methodological recommendations for the implementation of a network meta-analysis. FSBI TSEKKMP of the Ministry of Health of Russia; 2019. р. 1–68. (In Russ.)

Supplementary files

Supplementary Files
1. Рис. 1. Форест-диаграмма сетевого метаанализа, построенная относительно контроля для оценки влияния на параметры презентеизма

Download (25KB)
2. Рис. 2. Форест-диаграмма сетевого метаанализа, построенная относительно контроля для оценки влияния на параметры абсентеизма

Download (17KB)

© 2022 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies